Last reviewed · How we verify
Solu-medrone, Mabthera
At a glance
| Generic name | Solu-medrone, Mabthera |
|---|---|
| Sponsor | Newcastle University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (PHASE2)
- Rituximab Treatment of Focal Segmental Glomerulosclerosis (PHASE2)
- Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement (PHASE2)
- Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia (PHASE2)
- Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma (PHASE1)
- Stem Cell Transplantation for Stiff Person Syndrome (SPS) (PHASE1, PHASE2)
- Rituximab and Belimumab for Lupus Nephritis (PHASE2)
- Cardiac Safe Transplants for Systemic Sclerosis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Solu-medrone, Mabthera CI brief — competitive landscape report
- Solu-medrone, Mabthera updates RSS · CI watch RSS
- Newcastle University portfolio CI